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OBJECTIVES This study evaluates the feasibility and safety of a catheter-based laser system for percutaneous
myocardial revascularization and analyses the first clinical acute and long-term results in
patients with end-stage coronary artery disease (CAD) and severe angina pectoris.
BACKGROUND In patients with CAD and intractable angina who are not candidates for either coronary artery
bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA),
transmyocardial laser revascularization (TMR) has been developed as a new treatment that
results in reduced angina pectoris and increased exercise capacity. However, surgical
thoracotomy is required for TMR with considerable morbidity and mortality.
METHODS A catheter-based system has been developed that allows creation of laser channels in the
myocardium from within the left ventricular cavity. Laser energy generated by a Holmium:
YAG (Cardiogenesis Corporation, Sunnyvale, California) laser was transmitted to the
myocardium via a flexible optical fiber capped by an optic lens. The optical fiber was
maneuvered to the target area under biplane fluoroscopy through a coaxial catheter system
permitting movement in three dimensions.
RESULTS Thirty-four patients with severe CAD not amenable to either CABG or PTCA and
refractory angina pectoris (Canadian Cardiologic Society [CCS] Angina Scale Class III–IV)
were included in the study. Ischemic regions were identified by coronary angiography and
confirmed by thallium scintigraphy. The percutaneous myocardial revascularization (PMR)
procedure was successfully completed in all patients. In 29 patients, one vascular territory of
the left ventricle and in 5 patients, two vascular territories were treated. Eight to fifteen
channels were created in each ischemic region. Major periprocedural complications were
limited to an episode of arterial bleeding requiring surgical repair. There was one death early
after PMR, due to a myocardial infarction (MI) in a nontreated region. Clinical follow-up at
6 months (17 patients) demonstrated significant improvement of angina pectoris (CCS class
before PMR: 3.0 6 0.0, six months after PMR: 1.3 6 0.8, p , 0.0001) and increased exercise
capacity (exercise time on standard bicycle ergometry before PMR: 384 6 141 s, six months
after PMR: 514 6 158 s, p , 0.05), but thallium scintigraphy failed to show improved
perfusion of the laser treated regions.
CONCLUSIONS Percutaneous myocardial revascularization is a new safe and feasible therapeutic option in
patients with CAD and severe angina pectoris not amenable to either CABG or PTCA.
Initial results show immediate and significant improvement of symptoms and exercise
capacity but evidence of improved myocardial perfusion is still lacking. (J Am Coll Cardiol
1999;34:1663–70) © 1999 by the American College of Cardiology
In the majority of patients with coronary artery disease
(CAD), angina pectoris is relieved by coronary artery bypass
grafting surgery (CABG), percutaneous coronary angio-
plasty (PTCA) or medical therapy. However, a small
number of patients remain in whom CAD is not amenable
to either intervention due to severely diseased or totally
occluded vessels. Quality of life in these patients is impaired by
persisting angina pectoris and by the absence of a reasonable
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perspective for improvement of their symptom. For these
patients, transmyocardial laser revascularization (TMR),
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first introduced by Mirhoseini et al. (1), may offer a new and
effective treatment. In TMR, laser energy is used to create
transmural channels from the epicardial surface to the
ventricular chamber. The intention to provide additional
perfusion channels to the ischemic myocardium needed
revision soon after this form of treatment was introduced
into clinical practice because nearly all channels were found
to be occluded early after their creation (2–6). Today
various other mechanisms are in debate, such as denerva-
tion, neoangiogenesis and placebo effects in order to account
for the clinical improvement experienced by the majority of
patients.
One major drawback of TMR is the need for thoracot-
omy in order to gain access to the epicardial aspect of the
heart. Therefore, a catheter-based system has been devel-
oped that allows the controlled creation of laser channels
into the myocardium from the ventricular chamber (7,8).
This technique, termed “percutaneous myocardial revascu-
larization” (PMR), utilizes a Holmium-YAG laser recently
introduced in TMR (9), which allows the laser energy to be
transmitted to the heart via optical fibers. The design of the
system allows access to all aspects of the endocardial surface.
This study reports the acute and long-term results of the
first patients treated with PMR.
METHODS
Patients. Percutaneous myocardial revascularization was
performed in 34 patients (26 men, 8 women) with severe
disabeling angina pectoris (Canadian Cardiologic Society
[CCS] Angina Scale class III or IV) while receiving at least
two antianginal medications at the maximum tolerated
doses. Demographic and clinical data of the patients are
given in Table 1. All patients had severe CAD on coronary
angiography which was not amenable to either PTCA or
CABG due to diffuse disease, complete occlusion, lack of
graftable vessels or any combination thereof. Additional
selection criteria were: 1) normal or only moderately im-
paired left ventricular performance (ejection fraction
$35%), 2) stress induced myocardial perfusion defects on
thallium-201 scintigraphy, and 3) wall thickness in the
PMR target region .8 mm as determined by echocardiog-
raphy. The “target region” was defined as the region of stress
induced myocardial perfusion defects on thallium-201 scin-
tigraphy which was not amenable to CABG or PTCA.
Patients were also excluded from PMR if they had
unprotected left main coronary artery disease .50%, unsta-
ble angina pectoris or a change in antianginal medication
within the last three weeks, myocardial infarction (MI)
within the last three months, left ventricular thrombus,
severe peripheral vascular disease that excluded femoral
artery access, aortic stenosis that prohibited catheter access
to the left ventricle or renal insufficiency with serum
creatinine levels .2.5 mg/dl.
The study protocol was approved by the local ethics
committee before initiation of the study. All patients gave
written informed consent.
CardioGenesis PMR System. The design of the Cardio-
Genesis PMR System (CardioGenesis Corporation, Sunny-
vale, California) is shown in Figure 1A. The PMR guiding
catheters are available with various angulations of the
catheter tip. Guiding catheter and laser delivery catheter are
freely movable against each other so that all areas within the
left ventricular cavity can easily be reached. The laser energy
is delivered through an optical fiber capped by a lens with a
gold marker and an array of nitinol “petals” 3 mm from the
tip (Fig. 1B). The purpose of these petals is to retard
excessive advancement of the laser fiber into the myocar-
dium and to stabilize the lens in the endocardial trabeculae.
PMR procedure. A 9 F sheath was introduced in the
femoral artery for the PMR guiding catheter and a diag-
nostic 5 F coronary catheter was introduced in the contralat-
eral femoral artery using standard Seldinger technique.
Patients were heparinized with 10.000 IE intravenously.
The guiding catheter was placed in the left ventricle after
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CAD 5 coronary artery disease
CCS 5 Canadian Cardiologic Society
ECG 5 electrocardiogram
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
n.s. 5 not significant
PET 5 positron emission tomography
PMR 5 percutaneous myocardial revascularization
PTCA 5 percutaneous transluminal coronary
angioplasty
TMR 5 transmyocardial revascularization
SPET 5 single photon emission tomography
Table 1. Clinical and Demographic Data of 34 Patients Treated
With PMR
Age 64.3 6 7.5 yr (range 50–81)
Gender 28 men/8 women
Ejection fraction 63% 6 7%
CCS class 3.2 6 0.4
Coronary angiography
1-Vessel disease 4 pat (11.8%)
2-Vessel disease 8 pat (23.5%)
3-Vessel disease 22 pat (64.7%)
Previous interventions
CABG 22 pat (64.7%)
PTCA 11 pat (32.3%)
Localization of ischemia
Anterior wall 17 pat (50%)
Lateral wall 8 pat (23.5%)
Inferior wall 14 pat (41.2%)
CABG 5 coronary artery bypass grafts; CCS 5 Canadian Cardiologic Society
Angina Scale; pat 5 patients; PTCA 5 percutaneous transluminal coronary angio-
plasty.
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crossing the aortic valve with a standard 6 F pigtail catheter
and connected to a heparin drip (1500 IE Heparin/500 ml
saline). Left ventriculography and coronary angiography
were performed in two orthogonal views using biplane
imaging to visualize the target region for PMR and the
corresponding coronary anatomy. These two views were not
changed throughout the procedure. A transparent film was
placed over a stored image on the video monitor and a
“map” of the target region was traced. After correction for
magnification, a distance of 1 cm was marked on the films.
Then the laser delivery catheter containing the laser fiber
was inserted and also connected to a heparin drip. The
position of the laser catheter was assessed using biplane
flouroscopy. After aiming the laser catheter towards the
target region, the laser fiber was advanced until it made
contact with the endocardial surface. A burst of two pulses
of laser energy (2 Joules/pulse) was delivered, the laser fiber
was advanced 2–3 mm and another burst of two pulses was
delivered. Laser pulses were triggered by the electrocardio-
gram (ECG) signal during systole. The location of the laser
channels was recorded in the two orthogonal views on the
transparent films. Then the laser fiber was retracted and the
catheter assembly repositioned to create the next channel.
Care was taken to space channels at approximately equal
distances of about 1 cm from each other by defining the
position of the radio-opaque markers in orthogonal views.
Channel numbers were limited by the 1 cm spacing require-
ment. Echocardiograms were performed during and imme-
diately after the procedure in order to exclude perforation of
the ventricular wall and ensuing pericardial tamponade.
After the procedure, patients were observed for 24 h in the
coronary care unit. Serial ECGs, cardiac enzyme levels and
echocardiograms were obtained in the first 24 h after PMR.
Follow-up. Follow-up visits were scheduled after three and
six months. Follow-up consisted of assessment of clinical
status, echocardiography, bicycle exercise test and thallium
scintigraphy. Clinical status was assessed by recording the
patient’s symptoms, medication and use of additional nitro-
glycerin to treat anginal attacks. Severity of angina was
classified according to the CCS Scale. Use of additional
nitrate to cover anginal attacks was recorded semiquantita-
tively as I 5 no additional nitrates, II 5 additional nitrates
,1x/week, III 5 1–2x/week, IV 5 .2x/week, V 5
1–3x/day and VI 5 .3x/day. Exercise performance was
assessed by symptom-limited bicycle ergometer test starting
at 10 W with increments of 25 W every 3 min.
Myocardial perfusion was assessed by thallium scintigra-
phy following symptom-limited bicycle ergometry and after
pharmacological stress by injection of 0.54 mg/kg body
weight of dipyridamole, respectively. During physical exer-
cise, the maximal level was limited by angina pectoris or
dyspnoe; no patient attained the age-adjusted maximal heart
rate. Single photon emission tomography (SPET) acquisi-
tion was performed 10 min and 4 h after injection by use of
a dual-head camera (ADAC Laboratories, Milpitas, Cali-
fornia). Data were reconstructed iteratively with attenuation
correction. Relative count densities were determined in 14
wall segments: anterior, lateral, inferior and septal wall
segments in an apical, a middle and a basal short axis slice,
respectively and in two additional apical (anteroapical,
inferoapical) segments. For follow-up studies count rates
were related to that of an initially well perfused septal wall
segment that was not directly affected by PMR. All scinti-
graphic studies were analyzed by a physician unaware of the
timing of the study (i.e. before or after PMR).
Statistical analysis. Differences in angina pectoris severity
(CCS classification) at baseline and three and six months
after PMR, respectively, were compared using the sign-test.
Differences in use of additional nitroglycerin, exercise du-
ration in bicycle ergometry and left ventricular ejection
fraction (LVEF) at baseline and three and six months after
PMR, respectively, were compared using the Friedman-test
and the Wilcoxon-test. Differences in CK-levels before and
after PMR were compared using Student t test. The global
level of statistical significance was set at 5%. To allow for
repeated comparisons, Bonferroni correction on all p values
relating to repeated analysis was used.
A retrospective power calculation was performed to
determine the power of the current sample size to detect
clinically relevant differences in ejection fraction or thallium
uptake (after stress or at rest, respectively) at a significance
level of 5%. For ejection fraction, the power was 30% to
Figure 1. (A) Percutaneous myocardial revascularization catheter
system consisting of guiding catheter (blue), laser catheter (white)
and laser fiber (tip) showing multiple possibilities for longitudinal
and rotational adjustments. (B) Tip of the laser fiber with lens and
nitinol petals.
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detect a difference in ejection fraction of 5%. The powers to
recognize a difference of 5% for thallium uptake after stress
or at rest were 19% and 36%, respectively. All statistical tests
were performed using SPSS version 8.0 (SPSS Inc., Chi-
cago, Illinois).
RESULTS
PMR procedure. The PMR procedure was successfully
completed in all planned patients. In 27 patients only one
region of the left ventricle was treated with PMR. The
target region in these patients was the anterior wall in 11
patients, the lateral wall in 4 patients and the inferior wall in
12 patients. In seven patients, two regions of the left
ventricle were treated with PMR, the anterior and lateral
wall in four patients, the anterior and inferior wall in two
patients and the lateral and inferior wall in one patient,
respectively.
A mean of 10.4 6 2.7 (range 8 to 15, median 10) laser
channels were created in each region. Mean duration of the
procedure was 51 6 30 (range 13 to 150, median 48) min
with procedure times declining from 97 6 35 (range 65 to
150, median 80) min in the first five patients to 20 6 6
(range 13 to 31, median 17) min in the last five patients as
a result of the learning curve.
Total creatine kinase levels rose from 72 6 21 U/l before
PMR to 137 6 45 U/l after PMR in 33 of the 34 patients
(upper limit of normal 196 U/l). In one patient with
peripheral artery disease there was a significant retroperito-
neal bleeding from the 5 F femoral access site necessitating
surgical repair. In this patient, total creatine kinase levels
rose from 56 U/l before PMR to 1,236 U/l without
significant rise in CK-MB levels probably as a result of
skeletal muscle damage. A new left bundle branch block
developed in one patient, and ST segment depression not
corresponding to the treated region developed in another
patient.
Patients were discharged from the hospital 3.5 6 2.9 days
(range 2 to 15 days, median 3 days) after the PMR
procedure.
Adverse reactions. There was no periprocedural mortality
in the patients treated with PMR. One episode of bleeding
originating from the 5 F left femoral artery access site
required surgical repair. Minor periprocedural complica-
tions were: 1) one temporary bundle branch block attributed
to catheter pressure on the ventricular septum which re-
solved after change in catheter position, 2) one single
episode of nonsustained polymorphic ventricular tachycar-
dia also precipitated by mechanical contact with the ven-
tricular wall, 3) one third degree atrioventricular block
lasting 2–3 min; in this patient a temporary pacemaker was
inserted, 4) in six patients a small pericardial effusion
(,10 mm) developed within 24 h following the interven-
tion. In all patients the pericardial effusion was not detect-
able immediately after the procedure; it did not create
hemodynamic impairment and resolved spontaneously
without further treatment, and 5) one episode of transient
renal failure attributed to the use of contrast medium
(creatinine levels rose from 220 mg/dl before PMR to
450 U/l after PMR).
Late results: three months after PMR. Twenty-five pa-
tients have completed follow-up 3 months after PMR
treatment (Table 2). In these patients, severity of angina
pectoris decreased from CCS class 3.1 6 0.3 before PMR to
1.8 6 0.8 after PMR (p , 0.001). Twenty-one patients
reported improvement in their CCS class; four patients
reported no change. Symptoms did not deteriorate in any of
the patients. Use of additional nitroglycerin decreased from
4.7 6 0.9 before PMR to 2.7 6 1.4 after PMR (p , 0.001).
Nineteen patients used less additional nitroglycerin after
PMR; six patients reported no change in nitroglycerin use
after PMR. No patient used more additional nitroglycerin
than before PMR. Exercise time on bicycle ergometry rose
from 373 6 125 s before PMR to 470 6 163 s after PMR
(p , 0.05).
Left ventricular ejection fraction determined echocardio-
graphically was 59% 6 12% before PMR and 60% 6 14%
after PMR (not significant [n.s.]). In seven patients with
initially impaired ventricular performance (LVEF ,50%)
LVEF was 43% 6 7% before PMR and 42% 6 13% after
PMR (n.s.).
Three months after PMR, 201Tl scintigraphy was done
only with pharmacological stress. Compared with the non-
lasered septum, tracer uptake under stress was 74% 6 14%
compared with 73% 6 11% before PMR (n.s.). Perfusion at
rest after three months was 84% 6 10% compared with
88% 6 9% before PMR (n.s.).
Late results: six months after PMR. Follow-up data 6
months after PMR are available for 17 patients. Six months
after PMR, patients reported angina pectoris of CCS class
1.3 6 0.8 compared with 3.0 6 0.0 before PMR (p ,
0.001) and 1.7 6 0.8 three months after PMR (n.s. vs. six
months after PMR) (Fig. 2). Additional use of nitrates had
decreased from 4.6 6 0.9 before PMR to 2.9 6 1.4 after
three months (p , 0.001) and to 2.4 6 1.4 six months after





CCS class 3.1 6 0.3 1.8 6 0.8
Use of nitrates 4.7 6 0.9 2.7 6 1.4
Exercise capacity 373 6 125 s 470 6 163 s
Ejection fraction 59 6 12 60 6 14
Thallium uptake (stress) 74 6 14% 73 6 11%
Thallium uptake (rest) 84 6 10 88 6 9%
Use of nitrates was recorded on a semiquantitative scale (see Methods section).
Exercise capacity denotes exercise time on standard bicycle ergometry. Ejection
fraction was determined echocardiographically. Thallium uptake was determined as
tracer uptake in the laser-treated regions compared with the nonlasered septum
(septum 5 100%).
CCS 5 Canadian Cardiologic Society Angina Scale.
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PMR (n.s. vs. three months after PMR) (Fig. 2). Ejection
fraction did not change from 56% 6 11% before PMR to
57% 6 13% after three months and 57% 6 13% six months
after PMR. Exercise time on bicycle ergometry rose from
384 6 141 s before PMR to 509 6 152 s after three months
(p , 0.005) and to 514 6 158 s after six months (n.s. vs.
three months after PMR) (Fig. 3).
Tracer uptake compared with the non-lasered septum in
201Tl scintigraphy after pharmacological stress six months
after PMR was 78% 6 14% compared with 75% 6 13%
before PMR (n.s.) and 76% 6 12% three months after
PMR (n.s.) (Fig. 4A). Tracer uptake six months after PMR
after bicycle ergometry was 76% 6 11% compared with
79% 6 10% before PMR (n.s.) (Fig. 4B).
Perfusion at rest after six months was 89% 6 8%
compared with 89% 6 9% before PMR and 91% 6 9% after
three months (n.s.) (Fig. 4).
Adverse events. One patient with diffuse three vessel
disease and previous CABG and PTCA who had under-
gone successful PMR treatment of the inferior wall was
admitted to another hospital seven days after PMR with
acute anterior MI and died in cardiogenic shock. One
patient was readmitted to the hospital with congestive heart
failure 6 weeks after PMR treatment. He felt well until one
week before admission when he noticed an irregular pulse
and progressive dyspnoe. Electrocardiogram disclosed atrial
fibrillation with ventricular rates of about 130 beats/min. A
normal sinus rhythm could not be restored, but control of
ventricular rate with digitalis resulted in resolution of
symptoms and the patient was discharged after five days.
Another patient was hospitalized three weeks after PMR
treatment also for congestive heart failure. In this patient
with an ejection fraction of 35% before PMR, diuretic
medication had been withdrawn by his primary care physi-
cian. After reinstitution of diuretics the symptoms resolved.
DISCUSSION
In the majority of patients with CAD, symptoms of angina
pectoris are treated effectively by angioplasty or CABG.
However, in some patients the extent of CAD or diffuse
involvement of the coronary arteries renders these patients
unsuitable for PTCA or CABG, respectively. Furthermore
other patients after multiple coronary interventions may
Figure 2. Angina pectoris and use of additional nitrates of 17
patients at baseline and three and six months after percutaneous
myocardial revascularization, respectively. Anginal symptoms were
recorded according to the Canadian Cardiologic Society Angina
Scale (CCS class). Use of nitrates was recorded on a semiquanti-
tative scale (see Methods section). Solid box 5 CCS class; striped
box 5 use of nitrates.
Figure 3. Exercise time on standard bicycle ergometry of 17
patients at baseline and three and six months after percutaneous
myocardial revascularization, respectively (Box-Whisker-Plot).
Figure 4. Myocardial perfusion in 201Tl-scintigraphy of 17 pa-
tients at baseline and three and six months after percutaneous
myocardial revascularization, respectively. Myocardial perfusion
was quantitated by measurement of 201Tl uptake in the laser-
treated regions compared with the non-lasered septum (septum 5
100%). (A) Stress induced by injection of 0.54 mg/kg body weight
of dipyridamole. Striped box 5 stress; solid box 5 rest. (B)
Ischemia induced by standard bicycle ergometry. Striped box 5
exercise; solid box 5 rest.
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present with a situation where coronary morphology pre-
cludes further interventions. If medical therapy fails to
control symptoms, quality of life is impaired in these
patients by persisting angina pectoris and decreased exercise
capacity as well as by the absence of a reasonable perspective
for improvement in the future.
For these patients, transmyocardial laser revascularization
was developed that creates well defined debris-free
transmyocardial channels by use of laser energy from the
epicardial surface to the ventricular cavity. Clinical studies
consistently report a significant clinical benefit of the pa-
tients after PMR treatment resulting in less anginal symp-
toms, decreased use of additional nitrates and increased
exercise capacity (9–13). Myocardial perfusion studies with
201Tl scintigraphy, however, still show equivocal results.
Horvath et al. have reported improved perfusion in myo-
cardial regions treated with TMR (14) while other studies
could not find evidence of improved myocardial perfusion
after TMR using 201Tl scintigraphy or positron emission
tomography (PET) (13).
Most of the TMR procedures so far have been carried out
with CO2 laser systems. One of the drawbacks of these
lasers is that the laser energy cannot be transmitted through
optical fibers. The energy of the CO2 lasers has to be
delivered to the myocardium by use of a rather stiff mirror
system so that CO2 laser-based TMR can only be per-
formed with open chest surgery. More recently, TMR has
been carried out using excimer laser or Holmium: YAG
laser systems (9) which allow the use of optical fibers for
delivery of the laser energy.
To eliminate the need for open chest surgery, a catheter-
based system has been developed that allows the creation of
laser channels into the myocardium from the left ventricular
chamber. This PMR system uses a Holmium: YAG laser
(wavelength 2.1 mm) that allows the use of a fiber optic
system to deliver the laser energy to the myocardium. The
PMR system is designed to create laser channels with a
maximal channel depth of 7 to 8 mm from the endocardial
surface to the subendocardial and midmyocardial regions
where the ischemia is located.
Safety and feasibility of the PMR procedure. Although
there was initial concern that PMR may probably lead to
creation of completely transmural channels and may result
in pericardial effusion and pericardial tamponade, this study
did not encounter episodes of pericardial tamponade. Small
pericardial effusions were seen in some patients, not imme-
diately after the PMR procedure but developing during the
first 24 h after PMR. All these small pericardial effusions
resolved spontaneously; no patient required pericardial
drainage. These pericardial effusions were probably caused
by a moderate inflammatory reaction to the creation of the
laser channels similar to the small pericardial effusions that
may develop after catheter ablation of ventricular tachyar-
rhythmias. If transmural channels had been created during
PMR the pericardial effusions should have been detectable
immediately after PMR and may have led to larger effusions
causing pericardial tamponade. However, two episodes of
significant pericardial effusions have been encountered in
other institutions during PMR procedures (S. Oesterle,
1998, personal communications) in a total of more than 200
procedures. After pericardial drainage, both patients could
be stabilized.
Biplane imaging was used for positioning of the laser
catheter. However PMR can also be performed easily with
only a single plane angiography unit. Before PMR, a
coronary angiography was performed because of initial
concern to avoid creating laser channels into the epicardial
arteries. After some experience with the procedure, this
coronary angiogram may not be absolutely necessary before
PMR.
Assessment of efficacy: creation of laser channels and left
ventricular function. Creatine kinase levels rose moder-
ately after PMR. This indicates on one hand that PMR
really creates laser channels into the myocardium. On the
other hand, ventricular damage produced by PMR was only
very limited which is also underlined by the fact that LVEF
did not change, either immediately after PMR nor in the
following months. Even in patients with impaired left
ventricular function before PMR, the creation of laser
channels did not lead to further deterioration of left ven-
tricular function.
Assessment of efficacy: anginal symptoms and exercise
capacity. Percutaneous myocardial revascularization re-
lieved anginal symptoms and increased exercise capacity in
most of the patients similar to TMR (10–12). This effect
was seen three months after PMR with some patients
experiencing further improvement of symptoms in the
following three months. No patient reported deterioration
of symptoms after PMR. However, it has to be noted that
this clear and significant increase in exercise capacity does
not necessarily prove increased myocardial perfusion. A
psychologic effect caused by the intensive and repeated
survey of the patients cannot be ruled out as a contributory
factor for the increased exercise capacity and decreased use
of additional nitrates seen in our patients.
Assessment of efficacy: myocardial perfusion. Myocardial
perfusion assessed by 201Tl scintigraphy did not demon-
strate improved perfusion after PMR but rather a tendency
towards reduced tracer uptake after laser revascularization.
Perfusion studies after TMR also do not report consistent
results towards improved perfusion after TMR. Improved
perfusion after TMR was found by Horvath et al. (12) but
other studies could not demonstrate improved perfusion
after TMR (13). In patients where TMR was performed
together with CABG in the same patients, Diegeler et al.
found improved perfusion in the myocardial areas treated
with CABG but not in the regions treated with PMR (9).
Indirect evidence of improved myocardial perfusion after
TMR may be derived from studies using dobutamine stress
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echocardiography, where reduced ischemic wall motion
abnormalities were found in laser treated regions (15).
Assessment of efficacy: mortality and morbidity after
PMR. Mortality and morbidity rates were low in these first
patients treated with PMR compared with TMR where
mortality rates of 10% in the first 30 days following TMR
were reported (11,12). However, one patient died in car-
diogenic shock because of an anterior MI one week after
PMR in the inferior wall. This patient had severe three
vessel CAD and had undergone bypass surgery four years
before PMR. The saphenous vein grafts to the left anterior
descending and the circumflex artery were patent with
moderate atherosclerotic lesions; the bypass to the right
coronary artery was occluded. Perfusion imaging before
PMR did not show stress induced ischemia in the anterior
wall, so PMR was performed only in the inferior wall. If the
anterior wall had been considered at risk angiographically, a
percutaneous coronary intervention or a another bypass
operation would have been discussed. Percutaneous myo-
cardial revascularization is not considered to have the ability
to protect against acute MI. Transmyocardial revasculariza-
tion also does not convey much protection against acute
coronary symptoms in patients with severe CAD.
In the course of this study, a clear learning curve was seen
with procedure times of about 30 to 40 min for the last
patients. This shows that PMR is a rapid procedure with
little discomfort for the patients compared with TMR. The
time required to perform PMR is only moderately longer
than the time needed for balloon angioplasty or angioplasty
using other devices.
Mechanisms. Despite considerable research efforts, the
pathophysiologic mechanisms responsible for the effect of
myocardial laser revascularization still remain poorly under-
stood. Initially it was postulated by Mirhoseini et al. (16)
that these channels may possibly function as conduits to
allow perfusion of the ischemic myocardium with oxygen-
ated blood from the left ventricular cavity probably similar
to the perfusion via sinusoids seen in reptilian hearts (17).
Although patent laser channels after TMR have been
reported (10,18), the initial concept has been questioned by
many authors who found occluded laser channels at various
time points after TMR (2–5,19). In animal studies, Kwong
et al. (20) showed that laser treatment leads to local
denervation of the myocardium which may be responsible
for the acute clinical benefit seen in patients treated with
TMR. On the other hand, histological evidence of
perichannel angioneogenesis after TMR has been found
that may contribute to the long-term benefit of TMR
(3,6,18,21). However, this study could not demonstrate
improved perfusion in the laser treated myocardial areas.
One explanation could be that 201Tl scintigraphy is not
sensitive enough to show improved perfusion in rather small
areas of the left ventricular wall. Positron emission tomog-
raphy allows the study of smaller volumes of the myocar-
dium and may show improved perfusion in small areas
treated with PMR. After TMR improved perfusion of
subendocardial regions of the myocardium compared with
subepicardial regions was reported in one study using PET
analysis (10), but this analysis has been questioned and
others could not find improved perfusion of laser treated
regions using PET (13). On the other hand it cannot be
excluded that the therapeutic effect of laser revascularization
is not due to improved perfusion. Finally, it cannot be ruled
out that part of the clinical improvement after TMR is
simply due to a “placebo effect” of the procedure itself.
Study limitations. One limitation of this pilot study is the
lack of a randomized control group. After the results of this
study, randomized studies have been started in Europe and
the U.S. to compare the effect of PMR with conventional
medical therapy in patients with end-stage CAD.
Canadian Cardiologic Society classification and data of
nitroglycerin use were based on patient questioning. There-
fore, a placebo effect or bias cannot be ruled out for these
data. 201Tl scintigraphy is probably not sensitive enough to
demonstrate changes in myocardial perfusion after PMR.
Studies with PET may allow more accurate quantification
of myocardial perfusion before and after PMR.
Long-term studies after PMR are still lacking so that a
beneficial effect of PMR on long-term mortality and sur-
vival still remains to be shown.
Conclusions. Percutaneous myocardial revascularization is
a new safe and feasible therapeutic technique for patients
with CAD and severe angina pectoris not amenable to
either CABG or PTCA. Initial results indicate clinical
benefit to the patients with improvement of symptoms and
increased exercise capacity, but evidence of improved myo-
cardial perfusion still remains to be demonstrated.
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